LUMO vs. EQ, SPRO, HOOK, ACRS, CUE, ANIX, MRNS, ALRN, TPST, and LABP
Should you be buying Lumos Pharma stock or one of its competitors? The main competitors of Lumos Pharma include Equillium (EQ), Spero Therapeutics (SPRO), Hookipa Pharma (HOOK), Aclaris Therapeutics (ACRS), Cue Biopharma (CUE), Anixa Biosciences (ANIX), Marinus Pharmaceuticals (MRNS), Aileron Therapeutics (ALRN), Tempest Therapeutics (TPST), and Landos Biopharma (LABP). These companies are all part of the "pharmaceutical preparations" industry.
Lumos Pharma (NASDAQ:LUMO) and Equillium (NASDAQ:EQ) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, community ranking, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and risk.
In the previous week, Equillium had 5 more articles in the media than Lumos Pharma. MarketBeat recorded 6 mentions for Equillium and 1 mentions for Lumos Pharma. Equillium's average media sentiment score of 1.32 beat Lumos Pharma's score of 1.25 indicating that Equillium is being referred to more favorably in the news media.
Equillium has a net margin of -32.01% compared to Lumos Pharma's net margin of -2,434.69%. Equillium's return on equity of -51.20% beat Lumos Pharma's return on equity.
Lumos Pharma has a beta of 0.66, indicating that its stock price is 34% less volatile than the S&P 500. Comparatively, Equillium has a beta of 1.77, indicating that its stock price is 77% more volatile than the S&P 500.
Lumos Pharma currently has a consensus target price of $18.00, indicating a potential upside of 700.00%. Equillium has a consensus target price of $3.90, indicating a potential upside of 160.00%. Given Lumos Pharma's higher probable upside, equities analysts plainly believe Lumos Pharma is more favorable than Equillium.
Lumos Pharma and Equillium both received 34 outperform votes by MarketBeat users. However, 82.93% of users gave Equillium an outperform vote while only 77.27% of users gave Lumos Pharma an outperform vote.
34.0% of Lumos Pharma shares are owned by institutional investors. Comparatively, 27.1% of Equillium shares are owned by institutional investors. 25.4% of Lumos Pharma shares are owned by insiders. Comparatively, 30.3% of Equillium shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Equillium has higher revenue and earnings than Lumos Pharma. Equillium is trading at a lower price-to-earnings ratio than Lumos Pharma, indicating that it is currently the more affordable of the two stocks.
Summary
Equillium beats Lumos Pharma on 11 of the 16 factors compared between the two stocks.
Get Lumos Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for LUMO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LUMO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lumos Pharma Competitors List
Related Companies and Tools
